Costs of healthcare-and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms

Clinical Infectious Diseases

Volumn 55, Issue 6, 2012, Pages 807-815

  Neidell, Matthew J ^a   Cohen, Bevin ^b   Furuya, Yoko ^c   Hill, Jennifer ^d   Jeon, Christie Y ^b   Glied, Sherry ^a   Larson, Elaine L ^a,b  

^a Columbia University School of Nursing ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c New York University ^*  (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPENEM; LEVOFLOXACIN; MEROPENEM; METICILLIN; OXACILLIN; SULTAMICILLIN; VANCOMYCIN;

ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOODSTREAM INFECTION; COMMUNITY ACQUIRED PNEUMONIA; COMMUNITY ASSOCIATED INFECTION; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; HEALTH CARE COST; HEALTHCARE ASSOCIATED INFECTION; HUMAN; INFECTION; KLEBSIELLA PNEUMONIAE INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BACTERIAL INFECTIONS; CASE-CONTROL STUDIES; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DATABASES, FACTUAL; DRUG RESISTANCE, BACTERIAL; FEMALE; HEALTH CARE COSTS; HOSPITAL CHARGES; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NEW YORK CITY; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; URINARY TRACT INFECTIONS;

EID: 84865460977     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis552     Document Type: Article

References (41)

1. Meyer E, Ziegler R, Mattner F, Schwab F, Gastmeier P, Martin M. Increase of patients co-colonised or co-infected with methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium or extended-spectrum beta-lactamase-producing Enterobacteriaceae. Infection 2011; 39:501-6.
2. Bourdon N, Fines-Guyon M, Thiolet JM, et al. Changing trends in vancomycin-resistant enterococci in French hospitals, 2001-08. J Antimicrob Chemother 2011; 66:713-21.
3. Ghafourian S, Bin Sekawi Z, Sadeghifard N, et al. The prevalence of ESBLs producing Klebsiella pneumoniae isolates in some major hospitals, Iran. Open Microbiol J 2011; 5:91-5.
4. Chung DR, Song JH, Kim SH, et al. High prevalence of multidrugresistant non-fermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 2011; 184:1409-17.
5. Rosenthal VD, Bijie H, Maki DG, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. Am J Infect Control 2011; 40:396-407.
6. Hota B, Lyles R, Rim J, et al. Predictors of clinical virulence in community-onset methicillin-resistant Staphylococcus aureus infections: the importance of USA300 and pneumonia. Clin Infect Dis 2011; 53:757-65.
7. Cohen B, Larson EL, Stone PW, Neidell M, Glied SA. Factors associated with variation in estimates of the cost of resistant infections. Med Care 2010; 48:767-75.
8. Landers T, Apte M, Hyman S, Furuya Y, Glied S, Larson E. A comparison of methods to detect urinary tract infections using electronic data. Jt Comm J Qual Patient Saf 2010; 36:411-7.
9. Apte M, Neidell M, Furuya EY, Caplan D, Glied S, Larson E. Using electronically available inpatient hospital data for research. Clin Transl Sci 2011; 4:338-45.
10. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
11. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.
12. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36:309-32. (Pubitemid 351763841)
13. 3M Health Information Systems. Available at: http://www.hcup-us. ahrq.gov/db/nation/nis/APR-DRGsV20MethodologyOverviewand Bibliography.pdf. Accessed 21 June 2012.
14. Roberts RR, Scott RD 2nd, Hota B, et al. Costs attributable to healthcare-acquired infection in hospitalized adults and a comparison of economic methods. Med Care 2010; 48:1026-35.
15. Perencevich EN, Stone PW, Wright SB, Carmeli Y, Fisman DN, Cosgrove SE. Raising standards while watching the bottom line: making a business case for infection control. Infect Control Hosp Epidemiol 2007; 28:1121-33. (Pubitemid 47580454)
16. White AR. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control. J Antimicrob Chemother 2011; 66:1948-53.
17. Kaier K, Wilson C, Chalkley M, et al. Health and economic impacts of antibiotic resistance in European hospitals-outlook on the BURDEN project. Infection 2008; 36:492-4.
18. Nathwani D. Health economic issues in the treatment of drug-resistant serious gram-positive infections. J Infect 2009; 59(suppl 1): S40-50.
19. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26:166-74. (Pubitemid 40445022)
20. Filice GA, Nyman JA, Lexau C, et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol 2010; 31:365-73.
21. Wassenberg MW, de Wit GA, van Hout BA, Bonten MJ. Quantifying cost-effectiveness of controlling nosocomial spread of antibiotic-resistant bacteria: the case of MRSA. PLoS One 2010; 5:e11562.
22. Rubio-Terres C, Garau J, Grau S, Martinez-Martinez L. Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study. Clin Microbiol Infect 2010; 16:722-8.
23. Resch A, Wilke M, Fink C. The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals. Eur J Health Econ 2009; 10:287-97.
24. Mauldin PD, Salgado CD, Durkalski VL, Bosso JA. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: relationships with antibiotic use and cost drivers. Ann Pharmacother 2008; 42:317-26. (Pubitemid 351429595)
25. Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillinsusceptible S. aureus bloodstream infection? Infect Control Hosp Epidemiol 2009; 30:453-60.
26. Butler AM, Olsen MA, Merz LR, et al. Attributable costs of enterococcal bloodstream infections in a nonsurgical hospital cohort. Infect Control Hosp Epidemiol 2010; 31:28-35.
27. Alam MF, Cohen D, Butler C, et al. The additional costs of antibiotics and re-consultations for antibiotic-resistant Escherichia coli urinary tract infections managed in general practice. Int J Antimicrob Agents 2009; 33:255-7.
28. Tumbarello M, Spanu T, Di Bidino R, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extendedspectrum-beta- lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 2010; 54:4085-91.
29. de Kraker ME, Wolkewitz M, Davey PG, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2011; 66:398-407.
30. Stone PW, Glied SA, McNair PD, et al. CMS changes in reimbursement for HAIs: setting a research agenda. Med Care 2010; 48:433-9.
31. Finch RG. True impact of antibiotic resistance on treatment outcomes and the cost of healthcare delivery. Curr Opin Infect Dis 2011; 24:95-6.
32. Goff DA. Antimicrobial stewardship: bridging the gap between quality care and cost. Curr Opin Infect Dis 2011; 24(suppl 1):S11-20.
33. Diazgranados CA. Prospective audit for antimicrobial stewardship in intensive care: impact on resistance and clinical outcomes [published online ahead of print 20 September 2011]. Am J Infect Control 2011.
34. Charani E, Edwards R, Sevdalis N, et al. Behavior change strategies to influence antimicrobial prescribing in acute care: a systematic review. Clin Infect Dis 2011; 53:651-62.
35. DiazGranados CA, Abd TT. Participation of clinical pharmacists without specialized infectious diseases training in antimicrobial stewardship. Am J Health Syst Pharm 2011; 68:1691-2.
36. Nulens E, Broex E, Ament A, et al. Cost of the meticillin-resistant Staphylococcus aureus search and destroy policy in a Dutch university hospital. J Hosp Infect 2008; 68:301-7.
37. McGinigle KL, Gourlay ML, Buchanan IB. The use of active surveillance cultures in adult intensive care units to reduce methicillin-resistant Staphylococcus aureus-related morbidity, mortality, and costs: a systematic review. Clin Infect Dis 2008; 46:1717-25. (Pubitemid 351706769)
38. Buhlmann M, Bogli-Stuber K, Droz S, Muhlemann K. Rapid screening for carriage of methicillin-resistant Staphylococcus aureus by PCR and associated costs. J Clin Microbiol 2008; 46:2151-4.
39. Huskins WC, Huckabee CM, O'Grady NP, et al. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med 2011; 364:1407-18.
40. Jain R, Kralovic SM, Evans ME, et al. Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med 2011; 364:1419-30.
41. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010; 8:260-71.